Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Mo… Read more
Innate Pharma (IPHYF) - Net Assets
Latest net assets as of June 2025: $5.14 Million USD
Based on the latest financial reports, Innate Pharma (IPHYF) has net assets worth $5.14 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($92.94 Million) and total liabilities ($87.79 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.14 Million |
| % of Total Assets | 5.53% |
| Annual Growth Rate | -4.23% |
| 5-Year Change | -94.34% |
| 10-Year Change | -87.74% |
| Growth Volatility | 59.16 |
Innate Pharma - Net Assets Trend (2005–2024)
This chart illustrates how Innate Pharma's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Innate Pharma (2005–2024)
The table below shows the annual net assets of Innate Pharma from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $8.83 Million | -79.41% |
| 2023-12-31 | $42.90 Million | -20.79% |
| 2022-12-31 | $54.15 Million | -49.60% |
| 2021-12-31 | $107.44 Million | -31.12% |
| 2020-12-31 | $155.98 Million | -28.26% |
| 2019-12-31 | $217.42 Million | +30.00% |
| 2018-12-31 | $167.24 Million | +94.56% |
| 2017-12-31 | $85.96 Million | -0.25% |
| 2016-12-31 | $86.17 Million | +19.57% |
| 2015-12-31 | $72.07 Million | -3.43% |
| 2014-12-31 | $74.63 Million | +85.24% |
| 2013-12-31 | $40.29 Million | +72.43% |
| 2012-12-31 | $23.36 Million | -12.25% |
| 2011-12-31 | $26.62 Million | -20.56% |
| 2010-12-31 | $33.52 Million | -28.87% |
| 2009-12-31 | $47.12 Million | +13.98% |
| 2008-12-31 | $41.34 Million | -16.66% |
| 2007-12-31 | $49.61 Million | -12.00% |
| 2006-12-31 | $56.37 Million | +180.93% |
| 2005-12-31 | $20.07 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Innate Pharma's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 36659500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.19 Million | 47.45% |
| Other Comprehensive Income | $27.00K | 0.31% |
| Other Components | $390.98 Million | 4425.84% |
| Total Equity | $8.83 Million | 100.00% |
Innate Pharma Competitors by Market Cap
The table below lists competitors of Innate Pharma ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JS Global Lifestyle Company Limited
PINK:JGLCF
|
$174.98 Million |
|
Central Hydropower JSC
VN:CHP
|
$174.98 Million |
|
Gulf Oil Lubricants India Limited
NSE:GULFOILLUB
|
$174.99 Million |
|
Bank Net Indonesia Syariah Tbk PT
JK:BANK
|
$175.00 Million |
|
AerSale Corp
NASDAQ:ASLE
|
$174.95 Million |
|
TYC Brother Industrial Co Ltd
TW:1522
|
$174.92 Million |
|
Beijing Kingfore HV & Energy Conservation Technology Co.Ltd.
SHE:001210
|
$174.91 Million |
|
Equasens S. A.
PA:EQS
|
$174.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Innate Pharma's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 51,901,000 to 8,834,000, a change of -43,067,000 (-83.0%).
- Net loss of 49,471,000 reduced equity.
- Other comprehensive income decreased equity by 468,000.
- Other factors increased equity by 6,872,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-49.47 Million | -560.01% |
| Other Comprehensive Income | $-468.00K | -5.3% |
| Other Changes | $6.87 Million | +77.79% |
| Total Change | $- | -82.98% |
Book Value vs Market Value Analysis
This analysis compares Innate Pharma's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 26.61x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.15x to 26.61x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $1.35 | $2.90 | x |
| 2006-12-31 | $3.17 | $2.90 | x |
| 2007-12-31 | $1.98 | $2.90 | x |
| 2008-12-31 | $1.61 | $2.90 | x |
| 2009-12-31 | $1.79 | $2.90 | x |
| 2010-12-31 | $0.90 | $2.90 | x |
| 2011-12-31 | $0.71 | $2.90 | x |
| 2012-12-31 | $0.62 | $2.90 | x |
| 2013-12-31 | $1.04 | $2.90 | x |
| 2014-12-31 | $1.49 | $2.90 | x |
| 2015-12-31 | $1.35 | $2.90 | x |
| 2016-12-31 | $1.60 | $2.90 | x |
| 2017-12-31 | $1.58 | $2.90 | x |
| 2018-12-31 | $2.85 | $2.90 | x |
| 2019-12-31 | $3.25 | $2.90 | x |
| 2020-12-31 | $1.98 | $2.90 | x |
| 2021-12-31 | $1.35 | $2.90 | x |
| 2022-12-31 | $0.68 | $2.90 | x |
| 2023-12-31 | $0.62 | $2.90 | x |
| 2024-12-31 | $0.11 | $2.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Innate Pharma utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -560.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -391.97%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 12.57x
- Recent ROE (-560.01%) is below the historical average (-52.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -30.55% | -471.46% | 0.05x | 1.23x | $-8.14 Million |
| 2006 | -10.72% | -97.53% | 0.09x | 1.23x | $-11.68 Million |
| 2007 | -17.98% | -62.41% | 0.23x | 1.27x | $-13.88 Million |
| 2008 | -23.83% | -76.23% | 0.21x | 1.47x | $-13.99 Million |
| 2009 | -31.04% | -189.55% | 0.12x | 1.36x | $-19.34 Million |
| 2010 | -40.75% | -316.16% | 0.09x | 1.43x | $-17.01 Million |
| 2011 | -26.22% | -59.45% | 0.20x | 2.26x | $-9.64 Million |
| 2012 | -13.69% | -30.83% | 0.21x | 2.07x | $-5.54 Million |
| 2013 | -7.18% | -23.19% | 0.22x | 1.39x | $-6.92 Million |
| 2014 | -26.33% | -2166.15% | 0.01x | 1.22x | $-27.11 Million |
| 2015 | -9.31% | -37.45% | 0.06x | 4.25x | $-13.91 Million |
| 2016 | 14.67% | 22.51% | 0.20x | 3.27x | $4.02 Million |
| 2017 | -56.29% | -148.28% | 0.13x | 2.97x | $-56.98 Million |
| 2018 | 1.82% | 3.82% | 0.18x | 2.70x | $-13.68 Million |
| 2019 | -9.55% | -30.10% | 0.17x | 1.85x | $-42.50 Million |
| 2020 | -41.02% | -91.70% | 0.23x | 1.97x | $-79.58 Million |
| 2021 | -49.15% | -436.01% | 0.05x | 2.49x | $-63.55 Million |
| 2022 | -107.30% | -117.05% | 0.24x | 3.84x | $-63.52 Million |
| 2023 | -14.59% | -12.28% | 0.35x | 3.38x | $-12.76 Million |
| 2024 | -560.01% | -391.97% | 0.11x | 12.57x | $-50.35 Million |
Industry Comparison
This section compares Innate Pharma's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Innate Pharma (IPHYF) | $5.14 Million | -30.55% | 17.07x | $174.96 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |